OEM/ODM Red Light Therapy Manufacturing: The End-to-End Buyer Playbook

This page is a map rather than a manual. Every phase links to a detailed article on this site, so you can go as deep as the decision in front of you requires.

Table of Contents

• 1. What This Playbook Is — and Is Not
• 2. Phase 1: Define the Brief and Target Market
• 3. Phase 2: Select the Model and the Supplier
• 4. Phase 3: Validate and Freeze the Configuration
• 5. Phase 4: Prepare Production Release
• 6. Phase 5: Support the Product After Launch
• 7. Figures to Keep Consistent
• 8. Where We Fit in This Sequence
• 9. References & External Links

---

1. What This Playbook Is — and Is Not

Buyers new to device manufacturing usually ask two questions first: how long will it take, and what will it cost. Both are reasonable, and neither can be answered honestly at the start of a project — the answer depends on the product, the configuration, the market and the amount of change requested. Any page that offers a figure before it knows those four things is offering an average of other people’s projects.

What can be described precisely is the sequence of decisions. Five phases, each producing an output that the next phase consumes. The table below is the map; the sections after it give each phase two paragraphs and a route to the detail.

Phase	The Decision It Produces	Where the Detail Is
1. Brief	What the product is, who it serves, which markets it enters, and which claims you intend to make.	Product requirements framework; the business-case roadmap
2. Sourcing	Which starting point and which supplier, with ownership of design, tooling and files agreed.	OEM/ODM decision matrix; private label vs custom; factory vs trading model
3. Validation	That the product meets the requirements, and that the configuration is frozen.	What “effective” means; mask vs panel testing; the stage-gate process
4. Release	Who authorises a batch to ship, against which criteria, and how substitutions are controlled.	Risk-based audit plan; supplier audit checklist; session-duration labelling protocol
5. Support	How the product is maintained, and how you learn from what happens to it.	Supply-continuity questions; contraindications and warnings; safety-question communication

---

2. Phase 1: Define the Brief and Target Market

Describe the intended use, the target customer, the mandatory requirements, the sales channels and the markets. Then do the part most briefs skip: identify the claims the brand expects to make, and what evidence each one would need. Deciding that here is cheap; discovering it at the copywriting stage usually means changing the positioning.

The output is a version-controlled brief that a supplier can quote against — with mandatory requirements separated from preferences, and open questions visible rather than absorbed into the wording.

Go deeper:
the product requirements framework for turning feature words into testable requirements, and
the brand-launch roadmap for the customer and commercial questions behind the brief.

---

3. Phase 2: Select the Model and the Supplier

Decide first whether an existing platform, a configurable version or custom development fits — the four starting points are more useful than the OEM/ODM labels, which are used inconsistently across suppliers. Then compare candidates on evidence rather than claims: relevant scope, quality controls, testing, change management and support.

Whatever the model, the contract has to name who owns the design, the tooling, the files, the documentation and the corrective actions. Ambiguity here appears at the first proposed substitution, which is the most expensive moment to resolve it.

Go deeper:
the OEM/ODM decision matrix,
private label versus custom development,
factory versus trading models, and
how to evaluate a manufacturer.

---

4. Phase 3: Validate and Freeze the Configuration

Write the acceptance criteria before the sample arrives, then verify function, output, materials, labelling, instructions and test documents against the requirements. A visual approval is a legitimate part of that evaluation and is not a substitute for technical or safety verification.

The phase ends with a frozen configuration — stated in writing, tied to a drawing revision, and understood by everyone who will later claim that “nothing has changed”.

Go deeper:
what “effective” must mean at each level,
why measurements must match treatment geometry, and
the stage-gate process with its exit criteria.

---

5. Phase 4: Prepare Production Release

Agree inspection, traceability, release criteria, nonconformance handling and the rule for component substitution. Confirm that the technical records and the product information describe the version actually being built — not the version that was approved.

Then set the communication and escalation paths, so that a change or a problem has somewhere to go before it has to.

Go deeper:
the risk-based audit plan,
the supplier audit checklist, and
the session-duration labelling protocol.

---

6. Phase 5: Support the Product After Launch

Plan complaint handling, warranty, spare parts, records and updates before the first customer has a problem. Monitor whether the product performs as expected, and whether the claims or the instructions need revision as real experience accumulates.

A supplier relationship worth keeping includes a process for learning from production and from customer outcomes. Without one, the second product repeats the first product’s assumptions.

Go deeper:
supply-continuity questions,
deriving warnings from risk analysis, and
how to answer a sensitive safety question.

---

7. Figures to Keep Consistent

Rainbowdo reports a monthly production capacity of 100,000 units and a starting MOQ of 500 units. Both are company-stated baselines, and both should be read the same way wherever they appear: as figures to confirm against a specific product, configuration and production slot, not as a promise that any order can start immediately.

On the regulatory side, the public FDA records are model-specific: K243423 and K253712 each cover a named list of mask models, and a clearance attaches to those models and indications rather than to the brand. Rainbow also reports a Traditional 510(k) SE Letter for K263313 covering six hair-cap models; the public entry had not been independently retrieved when this page was prepared, so the letter itself is the document to check, and the public reference should be added once FDA posts it.

Starting an OEM or ODM project? Visit our
Custom Light Therapy Manufacturing Page.

---

8. Where We Fit in This Sequence

Rainbow Technology runs ODM and OEM programmes from our Shenzhen facility, which means we are involved from Phase 2 onwards and occasionally earlier, when a brief needs a feasibility opinion before it is finalised. What we will not do is compress the sequence to win the order.

• A feasibility answer on the brief, not on a photograph. Including which requirements are routine, which need tooling, and which need validation.
• The starting point stated in writing, so Phase 2 produces a decision rather than an impression.
• Sample evaluation against your criteria, with deviations listed and a decision requested for each.
• Release criteria and change control agreed before the first lot, which is what makes Phase 4 meaningful.
• Sample and small-batch production from 500 units, with a stated capacity of 100,000 units per month; both figures depend on model, configuration, packaging and schedule, and are confirmed in a formal quotation.
• Compliance documentation matched to the exact model for your target market. Where a model holds a 510(k) record we provide the K-number so you can check its scope in the FDA’s public database; clearance is not the same as FDA approval, and the scope differs from model to model.

---

9. References & External Links